Testing combinations for resistant Gram-negative infections
Treatments studied
Part of Infections clinical trials.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a serious infection (in your blood or lungs) that is caused by a type of bacteria called Gram-negative, and that bacteria is resistant to common antibiotics like meropenem.
- You are currently receiving or about to start IV (intravenous) antibiotics.
- You are not pregnant, not in jail, and not receiving end-of-life care.
- You have not been in another drug study in the last 30 days.
- If you have pneumonia, it must have been in the hospital for at least 2 days before symptoms started.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This study tests two different pairs of strong antibiotics to see which works better at clearing hard-to-treat bacterial infections that don't respond to standard drugs. You would receive one of these two combinations and be monitored for how well it works and any side effects.
This study looks at two strong antibiotics, polymyxin B and colistin, given through a vein to treat serious infections like pneumonia or blood infections caused by bacteria that are resistant to many other antibiotics. The goal is to see how well they work and how safe they are.
This trial tests a combination of antibiotics (BV100, polymyxin B, and either ceftazidime/avibactam or cefiderocol) for serious lung or bloodstream infections caused by a tough-to-treat bacteria called Acinetobacter. The goal is to see if the combination is safe and works better than current treatments.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
Hear when a new Bloodstream Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.